RevOpsis, Kemwell Biopharma enter strategic partnership to expedite development of biologics for treatment of nAMD
Ophthalmology Times
by
35m ago
According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration ..read more
Visit website
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Ophthalmology Times
by
6h ago
This Los Angeles-based ophthalmologist and medical creator discusses the role of social media in combating misinformation and building health care practices ..read more
Visit website
Vyluma meets with FDA to discuss atropine sulfate ophthalmic solution 0.01% for the treatment of pediatric myopia
Ophthalmology Times
by
6h ago
The Type A meeting addressed questions the FDA had about the late-stage product candidate ..read more
Visit website
Preserving patients’ vision by monitoring glaucoma progression rate
Ophthalmology Times
by
6h ago
Three approaches to examination provide a comprehensive overview ..read more
Visit website
CTS 2024: Real-world performance of pegcetacoplan
Ophthalmology Times
by
6h ago
The retrospective real-world evaluation of the drug considered several important as-yet-unanswered questions ..read more
Visit website
Everything I thought I knew about thyroid eye disease was only half right
Ophthalmology Times
by
1d ago
Shift in the understanding of TED has led to a reevaluation of the Rundle curve ..read more
Visit website
VLOG: NeuroOp Guru: Isolated empty sella is not a sign of elevated ICP
Ophthalmology Times
by
2d ago
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss how isolated empty sella is not a sign of elevated ICP ..read more
Visit website
Using multiple imaging techniques to detect early microscopic abnormalities in diabetic retinopathy
Ophthalmology Times
by
3d ago
The mapping method revealed prominent microscopic abnormalities consistent with diabetic retinopathy ..read more
Visit website
Ocular Therapeutix updates on clinical developments and future plans for Axpaxli
Ophthalmology Times
by
4d ago
The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR ..read more
Visit website
AMA adopts new policy to ensure diversity in clinical trials and research
Ophthalmology Times
by
4d ago
Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials ..read more
Visit website

Follow Ophthalmology Times on FeedSpot

Continue with Google
Continue with Apple
OR